Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Genomma Lab InternacionalB de CVMEX:LABB +1.24%66 Price-to-Operating-Cash-Flow is 6.90 as of Sep. 04, 2026, which is 34% below its 10-year median of 10.42. GuruFocus rates MEX:LABB with a GF Score™ of 66/100 and a GF Value™ of MXN17.41 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 699 Drug Manufacturers companies, Genomma Lab InternacionalB de CV ranks better than 81.69% on this metric.
As of today (2026-09-04), Genomma Lab InternacionalB de CV's share price is MXN13.05.
Genomma Lab InternacionalB de CV's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Jun. 2026 was MXN1.89. Hence, Genomma Lab InternacionalB de CV's Price-to-Operating-Cash-Flow Ratio for today is 6.90.
The historical rank and industry rank for Genomma Lab InternacionalB de CV's Price-to-Operating-Cash-Flow or its related term are showing as below:
MEX:LABB'
s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 5.4 Med: 10.42 Max: 33.01
Current: 6.89
During the past 13 years, Genomma Lab InternacionalB de CV's highest Price-to-Operating-Cash-Flow Ratio was 33.01. The lowest was 5.40. And the median was 10.42.
MEX:LABB's Price-to-Operating-Cash-Flow is ranked better than 81.69% of 699
companies
in the Drug Manufacturers industry
Industry Median: 15.94
vs MEX:LABB: 6.89
Genomma Lab InternacionalB de CV's Cash Flow from Operations per share for the
three
months ended in Jun. 2026 was MXN0.39.
Its Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Jun. 2026 was MXN1.89.
During the past 12 months, the average Operating Cash Flow per Share Growth Rate of Genomma Lab InternacionalB de CV was -41.40% per year.
During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 0.50% per year.
During the past 5 years, the average Operating Cash Flow per Share Growth Rate was 10.40% per year.
During the past 10 years, the average Operating Cash Flow per Share Growth Rate was 7.80% per year.
During the past 13 years, Genomma Lab InternacionalB de CV's highest 3-Year average Operating Cash Flow per Share Growth Rate was 140.80% per year. The lowest was -31.00% per year. And the median was 10.65% per year.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genomma Lab InternacionalB de CV Price-to-Operating-Cash-Flow Chart
MEX:LABB vs ZTS, UTHR, VTRS: Price-to-Operating-Cash-Flow Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Genomma Lab InternacionalB de CV's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genomma Lab InternacionalB de CV Price-to-Operating-Cash-Flow vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Genomma Lab InternacionalB de CV's Price-to-Operating-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Genomma Lab InternacionalB de CV's Price-to-Operating-Cash-Flow falls into.
Genomma Lab InternacionalB de CV's Share Price of today is MXN13.05. Genomma Lab InternacionalB de CV's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN1.89.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Price-to-Operating-Cash-Flow of 6.90 mean?
Genomma Lab InternacionalB de CV (MEX:LABB) has a Price-to-Operating-Cash-Flow of 6.90 as of Sep. 04, 2026. Price-to-operating-cash-flow ratio is the ratio of share price to a company's per-share cash from operations. View historical data on Genomma Lab InternacionalB de CV and its competitors. This is 34% below median its historical median of 10.42. Over the past decade, Genomma Lab InternacionalB de CV's Price-to-Operating-Cash-Flow has ranged from 5.40 to 33.01. According to the industry distribution chart, Genomma Lab InternacionalB de CV ranks #128 out of 699 companies in the Drug Manufacturers industry, placing it in the top 18.3%.
Is Genomma Lab InternacionalB de CV's Price-to-Operating-Cash-Flow too high?
Genomma Lab InternacionalB de CV's current Price-to-Operating-Cash-Flow of 6.90 is 34% below median its 10-year median of 10.42. Over the past 10 years, this metric has ranged from a low of 5.40 to a high of 33.01. The Drug Manufacturers industry median Price-to-Operating-Cash-Flow is 15.94. Genomma Lab InternacionalB de CV's value of 6.90 is 56.7% below this industry median. Based on the distribution chart, Genomma Lab InternacionalB de CV ranks #128 out of 699 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Genomma Lab InternacionalB de CV has a GF Score™ of 66/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Genomma Lab InternacionalB de CV's Price-to-Operating-Cash-Flow compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Genomma Lab InternacionalB de CV ranks #128 out of 699 companies for Price-to-Operating-Cash-Flow. This places Genomma Lab InternacionalB de CV in the top 18% of its industry — outperforming the majority of peers. The industry median Price-to-Operating-Cash-Flow is 15.94. Genomma Lab InternacionalB de CV's value of 6.90 is 56.7% below this benchmark. Historically, Genomma Lab InternacionalB de CV's own Price-to-Operating-Cash-Flow has ranged from 5.40 to 33.01 over the past decade. While the company's 10-year median is 10.42 vs. the industry median of 15.94, Genomma Lab InternacionalB de CV has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Price-to-Operating-Cash-Flow for a Drug Manufacturers company?
The median Price-to-Operating-Cash-Flow among Drug Manufacturers companies is 15.94, based on 699 companies in the industry. Companies in the top quartile (top 25%) have a Price-to-Operating-Cash-Flow significantly above this median, while those in the bottom quartile fall well below. However, Price-to-Operating-Cash-Flow should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Genomma Lab InternacionalB de CV's current Price-to-Operating-Cash-Flow of 6.90 is 56.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Price-to-Operating-Cash-Flow mean?
A high Price-to-Operating-Cash-Flow can signal that a stock is expensive relative to its fundamentals. Price-to-operating-cash-flow ratio is the ratio of share price to a company's per-share cash from operations. View historical data on Genomma Lab InternacionalB de CV and its competitors. For the Drug Manufacturers industry, the median Price-to-Operating-Cash-Flow is 15.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Genomma Lab InternacionalB de CV's current Price-to-Operating-Cash-Flow is 6.90, which is 34% below median its own 10-year median of 10.42. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genomma Lab InternacionalB de CV stock overvalued right now?
Based on GuruFocus' analysis, Genomma Lab InternacionalB de CV (MEX:LABB) is currently considered Modestly Undervalued. The stock's GF Value™ is MXN17.41, compared to a current price of MXN13.05 — trading 25% below its estimated fair value. The current Price-to-Operating-Cash-Flow is 6.90, which is 34% below median its 10-year median of 10.42 and 56.7% below the Drug Manufacturers industry median of 15.94. Genomma Lab InternacionalB de CV's overall GF Score™ is 66/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Price-to-Operating-Cash-Flow calculated?
Price-to-Operating-Cash-Flow is calculated from a company's financial statements. For Genomma Lab InternacionalB de CV (MEX:LABB), the current Price-to-Operating-Cash-Flow is 6.90 as of Sep. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Genomma Lab InternacionalB de CV (MEX:LABB) Overvalued in 2026?
Based on GuruFocus' analysis, Genomma Lab InternacionalB de CV stock appears to be undervalued.
The current stock price of MXN13.05 is trading 25% below its estimated GF Value™ of MXN17.41.
GuruFocus considers Genomma Lab InternacionalB de CV to be Modestly Undervalued.
Key valuation signals for MEX:LABB:
Price-to-Operating-Cash-Flow: 6.90 (34% below median its 10-year median of 10.42)
GF Value™: MXN17.41 vs. price of MXN13.05 (25% below fair value)
Industry Position: 56.7% below the Drug Manufacturers median (#128 of 699)
No single metric tells the full story. See the MEX:LABB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Genomma Lab Internacional SAB de CV is a specialty and generic drug manufacturer. The company's stated goal is to improve and preserve the health and well-being of people through innovative, safe, and effective products. Genomma operates a wide variety of brands to serve different consumer needs, including pregnancy, pain medication, and deodorant. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.
66GF Score
Get the complete analysis for MEX:LABB
Price-to-Operating-Cash-Flow is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:LABB has been successfully added to your 
